Loading...

Hot news 29_april NIH clinical trial shows Remdesivir accelerates recovery from advanced COVID-19 Hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received placebo, according to a preliminary data analysis from a randomized, controlled trial involving 1063 patients, which began on February 21. The trial (known as the Adaptive COVID-19 Treatment Trial, or ACTT), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is the first clinical trial launched in the United States to evaluate an experimental treatment for COVID-19. Based upon their review of the data, they noted that remdesivir was better than placebo from the perspective of the primary endpoint, time to recovery, a metric often used in influenza trials Recovery in this study was defined as being well enough for hospital discharge or returning to normal activity level. Source:NIH 4 سال پیش

برای ارسال پاسخ شوید.
رشته ها و جمعیت گروه پزشکی
Loading...